Irish drugmaker Elan ( ELN) reported a second-quarter loss of $68.2 million, or 14 cents a share, narrower than a year-earlier loss of $71.5 million, or 15 cents a share, as revenue rose 14% and Tysabri sales increased 30%.

Recorded sales of Tysabri, the multiple sclerosis medication Elan co-markets with Biogen Idec ( BIIB), were $173.7 million in the second quarter, up from $133.4 million a year earlier.

Elan said second-quarter revenue from its biopharmaceuticals business rose by 16% in the quarter, while revenue from its drug technologies business increased by 10%.

Earlier this month, Elan received an investment of up to $1.5 billion from Johnson & Johnson ( JNJ), in which J&J will acquire all the rights to three of Elan's most advanced Alzheimer's drug candidates.

If you liked this article you might like

Experimental Tau Protein Drug Tangled Up in Late-Stage Alzheimer's Study Failure

Experimental Tau Protein Drug Tangled Up in Late-Stage Alzheimer's Study Failure

With Martin Shkreli Long Gone, Retrophin is an 'Interesting Opportunity'

With Martin Shkreli Long Gone, Retrophin is an 'Interesting Opportunity'

Despite Shkreli Drama, Retrophin Looks Interesting Now

Despite Shkreli Drama, Retrophin Looks Interesting Now

Celtic Tiger Tries to Roar Again

Celtic Tiger Tries to Roar Again

Cramer's 6 Stocks in 60 Seconds: PRGO CREE HOG GME ORCL MHK (Update 1)

Cramer's 6 Stocks in 60 Seconds: PRGO CREE HOG GME ORCL MHK (Update 1)